Kornimate/medical-research-clean huggingface dataset:
to evaluate plasmajet in achieving complete cytoreduction of advanced eoc- initial feasibility study

Conditions: Epithelial Ovarian Cancer

Summary: surgery for ovarian cancer involves a big cut on your tummy (abdomen) followed by removal of pelvic organs (womb, tubes and ovaries), abdominal organs (fat tissue {omentum}, appendix) and any other tissues involved with cancer. several studies worldwide have reported that women survive longer and enjoy a longer disease free interval before their disease returns if all visible disease is removed at the time of their surgery. achieving this is not easy and often there is widespread disease and the surgeons are unable to remove every tumour nodule present as it is attached to the surface of the bowel, diaphragm and other important extensive surgery with prolonged operating is associated with higher risks. plasma energy is commonly referred to as the 4th state of matter after solid, liquid and gas. when a gas is heated, it partially or wholly ionizes resulting in high energy particles like ions, electrons and atoms referred to as 'plasma'. plasmajet® (pj) is a new device which uses fine jet of neutral argon plasma from the handpiece that has been shown to have the ability to vaporise nodules close to sensitive organs like the bowel. it may offer the potential to treat the tumour nodules close to sensitive areas like the bowel. there have been no studies exploring its role in vaporising tumour nodules and its impact on survival. the pj may be used by the surgeon to seal bleeding tissues (coagulate) or to burn away thin layers of tissue (ablate) by vaporization. it is licensed for use to achieve effects of coagulation and ablation. it is similar to conventional surgical devices that are routinely used (called diathermy) to achieve these effects. the pj however is slightly different in that it may also be used on tissue to vaporise tumour nodules in women with ovarian cancer during surgery though the full extent of this role remains unclear.


Eligibility criteria:
inclusion criteria: * imaging+/- clinical +/- laparoscopic e/o pelvic mass and metastatic disease (figo iii/iv disease) at presentation. * confirmation of malignancy on histological/cytological criteria. * all women aged 18 or over with newly diagnosed figo stage iii to stage iv eoc undergoing surgical treatment. * all women fit to undergo treatment. * no synchronous malignancy likely to interfere with comparisons. * written and informed patient consent exclusion criteria: * patient choice * patient unfit for any treatment modality * patients who are medically unfit for surgery and would only be suitable for chemotherapy. withdrawal criteria * unforeseen complications in the individual patient will be recorded and then analysed. * life threatening situation to the patient, due to any other unrelated complication. * patients are free to withdraw from the study at any time with no impact on their care whatsoever.

Keywords: eoc epithelial ovarian cancer surgery nil macroscopic residual disease stage 3/4 epithelial ovarian cancer requiring surgery
colorectal cancer screening using stool dna-based sdc2 methylation test

Conditions: Colorectal Cancer; Colon Polyp; Healthy

Summary: a study of colorectal cancer screening using stool dna-based sdc2 methylation test


Eligibility criteria:
inclusion criteria: * patient who agreed the clinical trial and signed informed consent * high risk patient for colorectal cancer (family history of colorectal cancer, history of adenomatous polyp excision, inflammatory bowel disease \> 15 years, or history of hereditary colorectal cancer) * patient who scheduled to receive colonoscopy * stool \> 20g before bowel preparation for colonoscopy exclusion criteria: * no high risk patient under 60 years * history of colorectal cancer * stool \< 20g or sample after bowel preparation * diarrhea or liquid stool which cannot be evaluated * patient who is judged as not suitable for clinical trial including a psychiatric disorder by a physician
high intensity interval training for people with stroke deficits

Conditions: Stroke

Summary: the purpose of this study is to compare the effects of an exercise training strategy called high-intensity interval training (hiit) to moderate intensity continuous exercise (mice), on walking function and cardiovascular fitness in stroke patients. hypothesis: hiit will result in significantly greater benefit to fitness and mobility than mice.

using a randomized design, the study will evaluate the effects of 3 hit sessions combined with 2 mice sessions per week on cardiovascular fitness and mobility compared to mice training 5 days/week. participants post-stroke will be randomly assigned to either mice (5 days per week (d∙wk-1)) or combined hiit (3 d∙wk-1) with mice (2 d∙wk-1). both groups will be exercising 5 times per week (walking on a treadmill with harness for fall protection); 3 times at the centre and 2 times at home. outcome measures will be conducted before and after 24 weeks of training.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke (hemorrhagic or ischemic), * ability to walk at least 100 m independently with or without an assistive device with no severe limitations due to pain, * living in the community at least 10 weeks post stroke (no upper limit) with a stroke-related motor impairment score of \<7 on the chedoke-mcmaster stroke assessment scale of the leg or foot or with hemiparetic gait pattern, * no severe communicative aphasia or comprehensive aphasia as noted in in clinical reports or referral form * no orthopedic issues that may be aggravated by hit * ability to provide informed consent exclusion criteria: * severe uncontrolled hypertension or orthostatic blood pressure decrease of \>20 mmhg * other cardiovascular morbidities which would limit exercise tolerance (e.g. horizontal or downsloping st-segment depression \>2 mm, symptomatic aortic stenosis, complex arrhythmias), * unstable angina, * severe proliferative retinopathy or uncontrolled blood glucose, * hypertrophic cardiomyopathy * lower extremity claudication * cognitive and/or behavioral issues limiting participation in exercise testing and training, prior unrelated neurological disorders or psychiatric illness * abdominal or inguinal hernia causing discomfort with routine activities. other issues will be considered case-by-case.
characterization of the charcot foot

Conditions: Charcot's Joint; Complications of Diabetes Mellitus

Summary: the project concerns a type of very debilitating diabetic foot complications called charcots osteoarthropathy (coa). this disease is characterized by a rapidly progressing destruction of the load bearing joints, primarily in the feet, resulting in loss of structure and remodeling. untreated this cascade leads to the collapse of the bones, meaning severe pain and walking disability for the patient. reconstruction is often very difficult or impossible, and furthermore the collapse can lead to chronic foot ulcers and infections, which in the worst case can be fatal. treatment options are currently limited to early diagnosis and physical offloading (immobilisation), assisted wound healing and surgical intervention. the purpose of this project is to investigate and describe the bone-related factors, which separate coa from other, less acute, diabetic foot changes. the investigators wish to describe the long term consequences of coa - both anatomically, physiologically and biochemically. the investigators will be doing this in a follow-up investigations on a group of coa patients tested 8 years ago. little is known of the long term changes to the bone structure after acute coa, and the investigators want to visualize to what extend the bone damage is permanent. to do this the investigators will be using dxa-scans, x-ray, blood tests including bone markers, neurophysiological tests and occlusion plethysmography.

please see above

Eligibility criteria:
inclusion criteria: * followed in the previous study exclusion criteria: * unable to attend follow-up
ultrahypofractionation and normal tissue toxicity

Conditions: Breast Cancer; Breast Cancer Female; Breast Cancer Stage II; Breast Cancer Stage III; Myocardial Fibrosis

Summary: this research is being done to see if proton beam radiation therapy (pbt) results in fewer changes to a participant's heart measured with mri-imaging than conventional or "photon" radiation therapy (xrt) for participants with non-metastatic left sided breast cancer. the names of the two study groups in this research study are: * proton radiation therapy (pbt) * conventional or "photon" radiation therapy (xrt)

this is a randomized phase ii trial comparing participants with stage ii-iii breast cancer treated with accelerated proton beam radiation therapy (pbt) versus accelerated conventional photon radiation therapy (xrt) inclusive of the regional lymph nodes. participants will be randomized into one of two study groups: proton beam radiation therapy versus photon radiation therapy. randomization means that participants are put into a group by chance. study procedures includes screening for eligibility, study treatment visits, cardiac magnetic resonance imaging (mri), blood tests, and questionnaires. the national cancer institute, american society of clinical oncology, and claflin grant are supporting this research by providing funding for the research study.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * non-metastatic breast cancer patients who are scheduled to receive conventional left-sided or bilateral breast/chest wall rt inclusive of treatment to the internal mammary lymph nodes (imns) * prior chemotherapy is permitted * ability to understand and the willingness to sign a written informed consent document * no contraindication to mri * patients with right-sided breast cancer or patients with left-sided patients not requiring treatment to the imns, but where cardiac anatomy is determined to be unfavorable by the study pi, will be considered eligible. exclusion criteria: * person who is pregnant or breastfeeding. * patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity. no cytotoxic therapy or radiotherapy may be used during radiation therapy. * contra-indication to gadolinium contrast (e.g., chronic kidney disease) * contra-indication to radiotherapy (e.g., scleroderma, p53 mutation)

Keywords: radiation therapy photon radiation therapy xrt proton beam radiation therapy pbt breast cancer breast cancer female breast cancer stage ii breast cancer stage iii myocardial fibrosis
canadian real world evidence study of brodalumab in plaque psoriasis to understand the impact on quality of life and work productivity

Conditions: Psoriasis

Summary: this is a phase iv, 12-month observational, prospective, open-label, multi-center study that will be conducted across approximately 50 sites in canada for an estimated study duration of 32 months. all eligible adult participants who are enrolling into the siliq patient support program (psp) and initiating brodalumab as per routine care may be offered participation in the study. if the participant agrees, their verbal consent and details will be entered into the study platform by the enrolling physician so that the participant can access the electronic informed consent form. participants who meet the eligibility criteria and provide electronic informed consent will be enrolled in the study. the study observation period will be 12 months (±15 days). data will be collected on approximately 500 participants across academic and community centers.


Eligibility criteria:
inclusion criteria: 1. aged ≥ 18 years old at the time of verbal consent to participate in the study. 2. initiating brodalumab as part of routine clinical care through the siliq (brodalumab) patient support program (psp) for the treatment of plaque psoriasis but has not yet received their first dose. decision to treat with brodalumab must have been reached prior to and independently of recruitment in the study. 3. must be able to read, understand, and communicate in english or french. 4. willing and able to provide informed consent on an online platform using an independent ethics committee (iec) or institutional review board (irb) approved electronic informed consent form (icf) in english or french. exclusion criteria: 1. not willing or able to complete epros (electronic patient reported outcomes) on an online platform (using a computer or mobile device). 2. participation in brodalumab phase iv study (nct04149587). 3. participation in an interventional clinical trial concurrently or within the last 30 days prior to providing verbal consent to participate in this study. 4. patient with crohn's disease or with clinically significant hypersensitivity to brodalumab or to any of the excipients or component of the container (contraindications as per the product monograph). 5. presence of any other serious and/or uncontrolled medical condition that, in the opinion of the investigator, prohibits the patient from participating in the study.
corrected flow time in the carotid artery as a predictor of fluid responsiveness in mechanically ventilated patients with low tidal volume in the intensive care unit

Conditions: Hypovolemic

Summary: the purpose of this study is to evaluate predictability of carotid corrected flow time for fluid responsiveness in mechanically ventilated patients with low tidal volume in the intensive care unit.


Eligibility criteria:
inclusion criteria: 1. adult patients with age more than 19 2. undergoing postoperative mechanical ventilation with low tidal volume 3. clinically diagnosed with hypovolemic status 4. if one of follow criteria is satisfied 1) systolic blood pressure \ 100bpm 4) urine output \ 2mmol/l 6) capillary refilling time \>3secs exclusion criteria: 1. body mass index \ 15 kg/m2 2. medical history of carotid artery stenosis \>50% or diagnosed while examination 3. cardiac arrhythmia other than normal sinus rhythm 4. moderate or severe valvular heart disease, intracardiac shunt, heart failure, pulmonary hypertension 5. moderate or severe chronic obstructive pulmonary disease 6. increased intracranial pressure 7. using vasopressor 8. pregnancy
assessment of novaloc and locator attachment systems

Conditions: Completely Edentulous Maxilla

Summary: the aim of the current study is to assess the effect of two types of attachments (locator, novaloc) on the supporting structures both mechanically using stress strain analysis and biologically through measuring bone height using cbct.

14 completely edentulous patients will be divided into two groups each group contains seven patients: group one: each patient will be restored with 4 implant retained maxillary overdenture using peek retention inserts attachment system and bone level ti-zr implants. group two: each patient will be restored with 4 implant retained maxillary overdenture using nylon retention insert attachment system and bone level ti implants. bone height in millimeters will then be evaluated around each implant using cone beam computed tomography at the time of placement of attachments, 6 months, 1 year

Eligibility criteria:
inclusion criteria: * completely edentulous patient with u shaped dental arch. * systemically free. * patients completed all extraction at least 6 months before surgery. * patients tempromandibular joint is free from any disease. * patient's mouth opening is proper for accessibility during surgery and implant placement. * sufficient bone level (length, and width) at implant placement site. * presence of enough bone height at implant site close to the maxillary sinus. * absence of sinus pneumatization. exclusion criteria: * heavy smoker. * patients with bone diseases. * patients having a history of parafunctional habits. * patients with diabetes mellitus. * patients on chemotherapy or radiotherapy. * patients on any medications that reduce wound healing. * patients without sufficient bone level (height, width). * patients with sinus pneumatization.

Keywords: implant overdenture maxilla novaloc locator peek
phase 2 study of indomethacin capsules to treat dental pain

Conditions: Dental Pain

Summary: the purpose of this study is to determine whether indomethacin test formulation capsules are safe and effective for the treatment of dental pain.


Eligibility criteria:
inclusion criteria: * patient is male or female between 18 and 50 years of age * for women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control * patient requires extraction of 2 or more third molars * patient must be willing to stay at the study site for at least 8 hours after dosing of the study drug exclusion criteria: * patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs * patient has a current disease or history of a disease that will impact the study or the patient's well-being * patient has used or intends to use any of the medications that are prohibited by the protocol * patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test * patient has taken another investigational drug within 30 days prior to screening
nobori dual antiplatelet therapy as appropriate duration

Conditions: Coronary Artery Disease

Summary: nippon trial is a prospective, randomized, trial comparing 6 and 18 months dual antiplatelet therapy (dapt) following nobori stent deployment.


Eligibility criteria:
inclusion criteria: * subjects \> 20 years old * undergoing percutaneous intervention with nobori deployment * no contraindication to prolonged dapt exclusion criteria: * subjects absolutely necessitating continuous dapt * planned surgery necessitating discontinuation of antiplatelet therapy after enrollment. * active pathological bleeding * status of cardiogenic shock at enrollment * pregnant women * life expectancy of \< 1.5 years * subjects unable to give informed consent * episode of stroke \< 6 months * subjects with allergies or hypersensitivity to material of coating, biolimus a9, and antiplatelet drugs. * subjects treated with other kind of des or bms during the index procedure * previous intervention with des \< 6 months. * study participation impractical per investigator judgment
investigation of the relationship between dysfunctional breathing and physical fitness parameters in healty adults

Conditions: Dysfunctional Breathing

Summary: this observational study aims to investigate the relationship between dysfunctional breathing and physical fitness parameters in healthy adults aged 18-35. participants will be evaluated using the nijmegen questionnaire to assess dysfunctional breathing symptoms, and their physical fitness will be measured using the alpha-fit test battery. respiratory muscle strength and pulmonary function will also be assessed. the findings may help healthcare professionals better understand dysfunctional breathing and develop targeted treatment programs.

dysfunctional breathing (db) is characterized by chronic alterations in the respiratory cycle, often leading to symptoms such as dyspnea, chest tightness, and hyperventilation. despite its prevalence, db is frequently underdiagnosed and mismanaged due to limited awareness among healthcare professionals. this cross-sectional study aims to evaluate the relationship between db symptoms and physical fitness in healthy young adults. a total of 38 participants diagnosed with db will be assessed at istinye university using the nijmegen questionnaire, alpha-fit test battery, spirometry, and measurements of maximum inspiratory (mip) and expiratory (mep) mouth pressures. data on sociodemographic characteristics will also be collected. the results of this study are expected to support clinicians in the accurate identification of db and provide insight for the development of personalized rehabilitation strategies that improve physical fitness and respiratory health.

Eligibility criteria:
inclusion criteria: * aged between 18-35 years * healthy individuals with no known systemic, neurological, or musculoskeletal disorders * nijmegen questionnaire score \>23 (indicative of dysfunctional breathing) * voluntary participation with informed consent exclusion criteria: * diagnosed with respiratory, cardiovascular, or metabolic disease * currently receiving physiotherapy or pulmonary rehabilitation * regular use of medication affecting breathing or exercise capacity * pregnancy

Keywords: alpha-fit physical fitness respiratory function mip mep hyperventilation young adults
sim (scratch in miscarriage) study

Conditions: Recurrent Miscarriage

Summary: there is increasing amount of evidence which suggests that miscarriage is related to a primary endometrial problem. recent cochrane meta-analysis (march 2015) has proven that endometrial scratch improves live birth in women who underwent ivf. the aim of the study is to find out if scratch of the endometrium prevents recurrent miscarriage.

the warwick bru-rh (biomedical research unit- reproductive health) hypothesis is that failed pregnancies are the result of failed decidualisation of the endometrium.

Eligibility criteria:
inclusion criteria: 1. provision of written informed consent 2. actively trying for a pregnancy exclusion criteria: 1. no active treatment in pregnancy 2. inherited or acquired thrombophilia 3. medical conditions- diabetes,hypertension,thyroid disorders 4. inability to tolerate internal examinations 5. uterine anomalies 6. previous entry or randomisation in the present trial
protocol to allow continued access of ficlatuzumab to p05538 patient

Conditions: Mullerian Mixed Tumor of Ovary

Summary: protocol to allow continued access of ficlatuzumab to p05538 patient

this treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol p05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.

Eligibility criteria:
inclusion criteria: * per original p05538 protocol exclusion criteria: * per original p05538 protocol
effects of bortezomib-based therapy on cellular immunity and response to dc/myeloma fusion vaccines in vitro

Conditions: Multiple Myeloma

Summary: the purpose of this study is to better understand what effects bortezomib, a drug used for multiple myeloma therapy, has on the immune system.

subjects on this study will be receiving treatment for multiple myeloma according to the standard of care with a regimen containing bortezomib. if a bone marrow sample is clinically indicated to guide treatment, an additional 1 tablespoon of the specimen will be obtained for further laboratory studies. approximately 3 tablespoons of blood will be taken for research purposes before therapy with bortezomib starts. when subjects return for follow-up after cycle 1, 2, and 3 and additional 3 tablespoons of blood will be taken for research purposes. optional samples of blood may be taken at follow-up visits after cycles 4, 5 and 6 and 1, 3 and 6 months after completing therapy. this study also includes a medical record review.

Eligibility criteria:
inclusion criteria: * newly diagnosed multiple myeloma * therapy with bortezomib alone or bortezomib/dexamethasone being initiated as the standard of care therapy for myeloma by their treating physician exclusion criteria: * hypersensitivity to bortezomib, boron or mannitol * treatment with other investigational drugs within 28 days before enrollment * diagnosed or treated for another malignancy within 6 months of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy * use of other myeloma directed therapy (except for dexamethasone) in combination with bortezomib

Keywords: mm bortezomib velcade